id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2019-E-3017-0005,FDA,FDA-2019-E-3017,Letter to U. S. Patent and Trademark Office from FDA CDER,Other,Letter(s),2023-12-29T05:00:00Z,2023,12,2023-12-29T05:00:00Z,,2023-12-29T14:13:37Z,,0,0,09000064863656c8
FDA-2019-E-3017-0004,FDA,FDA-2019-E-3017,Determination of Regulatory Review Period for Purposes of Patent Extension; Emgality,Notice,Determinations,2023-12-22T05:00:00Z,2023,12,2023-12-22T05:00:00Z,2024-02-21T04:59:59Z,2023-12-22T14:20:59Z,2023-28233,0,0,0900006486351116